0.8333
price down icon12.22%   -0.1122
 
loading
Schlusskurs vom Vortag:
$0.9455
Offen:
$0.93745
24-Stunden-Volumen:
111.76K
Relative Volume:
0.30
Marktkapitalisierung:
$1.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.38M
KGV:
-0.2187
EPS:
-3.81
Netto-Cashflow:
$-12.45M
1W Leistung:
-17.00%
1M Leistung:
-38.97%
6M Leistung:
-70.46%
1J Leistung:
-93.45%
1-Tages-Spanne:
Value
$0.79
$0.973
1-Wochen-Bereich:
Value
$0.79
$1.0697
52-Wochen-Spanne:
Value
$0.79
$13.12

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Name
Firmenname
Avenue Therapeutics Inc
Name
Telefon
781-652-4500
Name
Adresse
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Name
Mitarbeiter
3
Name
Twitter
@avenuethera
Name
Nächster Verdiensttermin
2024-12-11
Name
Neueste SEC-Einreichungen
Name
ATXI's Discussions on Twitter

Vergleichen Sie ATXI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATXI
Avenue Therapeutics Inc
0.83 1.95M 0 -10.38M -12.45M -3.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
499.71 130.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.37 75.53B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.25 35.07B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
239.24 31.72B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.63 26.76B 3.32B -860.46M -1.04B -8.32

Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten

pulisher
10:14 AM

Avenue Therapeutics stock hits 52-week low at $0.9 amid downturn - Investing.com

10:14 AM
pulisher
08:09 AM

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

08:09 AM
pulisher
Mar 07, 2025

Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Avenue Therapeutics Annji Intends To Terminate License Agreement With Co -March 07, 2025 at 04:36 pm EST - Marketscreener.com

Mar 07, 2025
pulisher
Mar 07, 2025

Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online

Mar 07, 2025
pulisher
Mar 05, 2025

Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - Nasdaq

Mar 05, 2025
pulisher
Mar 04, 2025

SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow

Mar 04, 2025
pulisher
Mar 03, 2025

Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 40.5% in February - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

KESTRA MEDICAL TECHNOLOGIES, LTD. Prices IPO at $14.00-$16.00 Per Share (KMTS) - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

Short Interest in ArrowMark Financial Corp. (NASDAQ:BANX) Expands By 62.6% - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

American Rebel Holdings, Inc. (NASDAQ:AREB) Sees Large Growth in Short Interest - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

Arbe Robotics Ltd. (NASDAQ:ARBE) Short Interest Up 56.5% in February - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Analyst Downgrade - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics stock hits 52-week low at $1.22 - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics (NASDAQ:ATXI) vs. Teva Pharmaceutical Industries (NYSE:TEVA) Head to Head Review - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World

Feb 28, 2025
pulisher
Feb 12, 2025

The Surprise Surge: How Travere Therapeutics Defied Wall Street Trends - Jomfruland.net

Feb 12, 2025
pulisher
Feb 12, 2025

Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

ATXIAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights - br.ADVFN.com

Feb 11, 2025
pulisher
Feb 06, 2025

Sionna Therapeutics Prices Upsized Initial Public Offering - GlobeNewswire

Feb 06, 2025
pulisher
Feb 05, 2025

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance

Feb 05, 2025
pulisher
Feb 05, 2025

Here’s Why Third Avenue Small-Cap Value Fund Re-established a Position in Five Point Holdings (FPH) - Yahoo Finance

Feb 05, 2025
pulisher
Jan 28, 2025

Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice - ACCESS Newswire

Jan 28, 2025
pulisher
Jan 28, 2025

Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com

Jan 28, 2025
pulisher
Jan 27, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Jan 27, 2025
pulisher
Jan 27, 2025

Trajan Group Director Increases Stake Through Options - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

How Are Things Looking For Zeta Global Holdings Corp (NYSE: ZETA) For The Short Term? - Stocks Register

Jan 27, 2025
pulisher
Jan 27, 2025

Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

Park Avenue Securities LLC Buys Shares of 1,684 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Park Avenue Securities LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World

Jan 26, 2025
pulisher
Jan 26, 2025

Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Assenagon Asset Management S.A. Sells 65,316 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025
pulisher
Jan 24, 2025

FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan

Jan 24, 2025
pulisher
Jan 24, 2025

Wall Street-Heavily Traded - WDRB

Jan 24, 2025
pulisher
Jan 24, 2025

PLRX (Pliant Therapeutics) Momentum Rank : 7 (As of Jan. 24, 2025) - GuruFocus.com

Jan 24, 2025
pulisher
Jan 24, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Fortune Brands plans Deerfield headquarters expansion, hundreds of new jobs; ‘A great endorsement of Lake County’ - Chicago Tribune

Jan 23, 2025
pulisher
Jan 22, 2025

Healthcare Triangle Faces Potential Delisting, Plans Annual Meeting - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Park Avenue Securities LLC - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Another strong year for K Street heading into Trump 2.0, tax fights - POLITICO

Jan 22, 2025
pulisher
Jan 21, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World

Jan 21, 2025
pulisher
Jan 21, 2025

Hennion & Walsh Asset Management Inc. Takes Position in Autolus Therapeutics plc (NASDAQ:AUTL) - Defense World

Jan 21, 2025
pulisher
Jan 21, 2025

Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Jan 21, 2025

Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Avenue Therapeutics Inc-Aktie (ATXI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
KRANZLER JAY D
Director
Nov 05 '24
Sale
2.24
61
137
559
KRANZLER JAY D
Director
Sep 30 '24
Buy
2.50
497
1,242
620
KRANZLER JAY D
Director
Sep 27 '24
Buy
2.40
3
7
123
$36.89
price up icon 5.68%
$306.88
price up icon 0.65%
$32.96
price up icon 1.36%
$20.41
price up icon 1.05%
$102.19
price up icon 1.10%
biotechnology ONC
$247.47
price down icon 0.28%
Kapitalisierung:     |  Volumen (24h):